Arrowhead Pharmaceuticals Inc (FRA:HDP1)
€ 24.66 4.54 (22.56%) Market Cap: 3.08 Bil Enterprise Value: 2.92 Bil PE Ratio: 0 PB Ratio: 17.54 GF Score: 48/100

Arrowhead Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript

Mar 12, 2019 / 08:20PM GMT
Release Date Price: €16.81 (+1.88%)
Gena Wang
Barclays Bank PLC, Research Division - Research Analyst

Good afternoon. My name is Gena Wang, SMID-cap biotech analyst of Barclays. It's my great pleasure to introduce our next speaker, Bruce Given, Chief Operating Officer and Head of R&D of Arrowhead.

Bruce D. Given
Arrowhead Pharmaceuticals, Inc. - COO

Good afternoon. Thank you for the invitation to speak. I've been asked to move very quickly through the slides so we have plenty of time for Q&A. So I'll go right ahead here, assuming I can get this to advance. There we go. Because I'm moving quickly, I would encourage any of you to be sure to take a look at our forward-looking statement.

So we're going to talk today about our platform, which is the TRiM platform. It's in cartoon form. It's quite simple. It's a double-stranded siRNA molecule that's been heavily modified to survive the body's many defense mechanisms against such molecules. And then we -- these double-stranded RNA molecules do not tend to traverse plasma membranes easily. So to get into cells, we target them to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot